Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen G DNL343

NCT05842941
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Not applicable Interventional

Deprescribing in Outpatient Internal Medicine Practices

NCT07226960
View directory record Official record
Conditions
Deprescribing
Interventions
medication review
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
75 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Not applicable Interventional

The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy

NCT05868369
View directory record Official record
Conditions
Hip Pain Chronic
Interventions
iVR Group, Standard pain management regimen
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Withdrawn Phase 2 Interventional

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04784754
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Not applicable Interventional

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

NCT04003350
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 31, 2026, 8:45 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Study for Post op Inflammation After Cataract Surgery

NCT05665270
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1%
Drug
Lead sponsor
Wyse Eyecare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247
View directory record Official record
Conditions
Keloid, Hypertrophic Scar, Cicatrix, Hypertrophic
Interventions
0.5% hydrocortisone, silicone, vitamin E lotion, Onion extract gel, Cetearyl alcohol lotion
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00005838
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 31, 2026, 8:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00428948
View directory record Official record
Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Riverside, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

NCT04875962
View directory record Official record
Conditions
Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
6
States / cities
Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 31, 2026, 8:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 2 Interventional

CPG 7909 Injection in Non-Small Cell Lung Cancer

NCT00070629
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
CPG 7909, Chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
17
States / cities
Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Oct 31, 2026, 8:45 PM EDT
Enrolling by invitation Not applicable Interventional

NQ Square TMS for MDD 1Dx3S Adults Multi-site Sham-controlled Protocol

NCT07369180
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active Accelerated rTMS Treatment, Sham Accelerated rTMS Treatment
Device
Lead sponsor
NeuroQore Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Campbell, California • Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Recruiting Not applicable Interventional

Chronic Non-Specific Neck Pain Treated With Tai Chi and Chiropractic Care

NCT05726331
View directory record Official record
Conditions
Neck Pain, Chronic Pain
Interventions
Chiropractic Care, Tai Chi, Enhanced Usual Care
Other
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

NCT01405053
View directory record Official record
Conditions
Lennox-Gastaut Syndrome
Interventions
Rufinamide, Any other approved Antiepileptic Drug
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Alternatives for Reducing Chorea in Huntington Disease

NCT01897896
View directory record Official record
Conditions
Chorea Associated With Huntington Disease
Interventions
SD-809
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 31, 2026, 8:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Escondido, California • Lancaster, California • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT00337194
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
monoclonal antibody SGN-30, placebo, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 31, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Phentermine/Topiramate for Uric Acid Stones

NCT04621929
View directory record Official record
Conditions
Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions
Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 8:45 PM EDT